Navigation Links

Biology Technology

Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014

3/5/2015
Chardon, Ohio (PRWEB) March 05, 2015 e2b teknologies , a premier Sage ERP reseller and Gold Development Partner located in Northeast Ohio, today announced a leading independent multi-specialty physician group practice has chosen e2b teknologies to support its upgrade to the latest version of Sage 100 ERP . As the largest independent group practice of its kind in the region, the organiz... [Comments]

Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval

3/5/2015
Thornton Cleveleys (UK) (PRWEB) March 05, 2015 The next implants made from the PEEK-OPTIMA® HA Enhanced implantable polymer have received the CE mark (European) approval. The CE mark is necessary for distributing products within the European Free Trade Association (EFTA) and the European Union. Following the Class IIb approval route, a CE mark has now been granted to implants supplied... [Comments]

Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm.

3/5/2015
Southlake, Texas (PRWEB) March 05, 2015 RMI specializes in Stemnexa™ non-surgical treatment of acute and chronic orthopedic conditions such as meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. Stemnexa may also be administered during orthopedic surgeries to promote better post-surgical outc... [Comments]

PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note

3/4/2015
INCLINE VILLAGE, Nev. , March 4, 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 174.8506 shares of common stock per $1,000 principal amount or approximately $5.72 per share, effective March 3, 2015. The conversion rate for the note i... [Comments]

Latest Clinical Information On Bioterrorism Threats

3/4/2015
BALTIMORE , March 4, 2015 In an article published and posted online today, senior scholars at the UPMC Center for Health Security review the clinical aspects of diseases caused by 5 major pathogens that can be used as bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published and posted online today on the website of t... [Comments]

UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity

3/4/2015
BALTIMORE , March 4, 2015 The UPMC Center for Health Security today announced the selection of its 2015 Fellows in the Emerging Leaders in Biosecurity Initiative (ELBI). As part of our commitment to fostering future leaders in the field of biosecurity, UPMC has selected 28 US and international emerging leaders in biosecurity from a wide array of backgrounds, includi... [Comments]

NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY

3/4/2015
BROOKLYN, N.Y. , March 4, 2015  Brooklyn residents now have a new place to go to treat their acute and chronic pain and injuries. Nunzio Saulle , M.D., a board-certified physiatrist, is proud to announce the grand opening of his NJS Physical Medicine and Rehabilitation (PM&R) practice in Brooklyn, NY on Thursday, March 5, 2015. Health Plus Management, LLC is manag... [Comments]

USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences

3/4/2015
SANTA BARBARA, CALIFORNIA (PRWEB) March 04, 2015 USDM Life Sciences , a leading global regulatory consulting firm in the life sciences industry, hired David Blewitt as Vice President of Cloud Compliance. Blewitt leads the Cloud Compliance Services and Solutions at USDM Life Sciences , which help life sciences companies utilize cloud based applications while maintaining compliance with g... [Comments]

Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies

3/4/2015
DUBLIN , Mar. 04, 2015 Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ) has announced the addition of Jain PharmaBiotech's new report "Biomarkers - Technologies, Markets and Companies" to their offering. This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an ind... [Comments]

Global Biologics and Biosimilars Industry Report 2015-2020

3/4/2015
DUBLIN , Mar. 04, 2015 Research and Markets ( http://www.researchandmarkets.com/research/jspg2c/global_biologics ) has announced the addition of the "Global Biologics and Biosimilars Industry Report 2015" report to their offering. The Global Biologics and Biosimilars Industry Report 2015 is a professional and in-depth study on the current state of the biologics and bio... [Comments]

Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program

3/4/2015
CALGARY , March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today announced that it has completed a collaborative research program with Emerald Logic, a leader in quantitative analytics.  Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix's complete clinical dataset including all measurements obtained from each of 798 patients who... [Comments]

Medicine Technology

Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor

3/4/2015
EVERETT, Washington , 5. März 2015 Unfors RaySafe, der globale Marktführer für Qualitätssicherung im Bereich diagnostische Röntgenstrahlung, stellte heute auf dem europäischen Kongress für Radiologie, dem European Congress of Radiology (ECR) in Wien , Österreich, einen neuen Strahlungsüberwachungssensor vor. Logo - http://pho... [Comments]

Hill-Rom Elects Stacy Enxing Seng to its Board of Directors

3/4/2015
CHICAGO , March 4, 2015  Hill-Rom Holdings, Inc. (NYSE: HRC ) announced today that Stacy Enxing Seng has been elected to its Board of Directors.  She most recently served as an Executive in Residence for Covidien, as well as President of Covidien's Vascular Therapies Division from 2012 to 2014, and President of Peripheral Vascular from 2010 to 2012. Ms. Enx... [Comments]

Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis

3/4/2015
WASHINGTON , March 4, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today announced top-line results of the Phase II proof of concept clinical study investigating the safety and efficacy of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis. Despite a highly significant and clinically meaningful improvement fro... [Comments]

Kalorama: Growing Elderly Population Drives Orthopedic Device Market

3/4/2015
NEW YORK , March 4, 2015  The strongest driver of demand in the global orthopedic device market is the increasing elderly population, according to Kalorama Information. The finding was made in a recent report from the healthcare market research publisher, Global Orthopedic Device Market . An aging population coupled with other risk factors such as obesity is contribu... [Comments]

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014

3/4/2015
BEIJING, March 4, 2015 China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year 2014. Fourth Quarter 2014 Financial Highlights Total sales in the fourth quarter of 2014 increased by 36.2%, or 36.8%... [Comments]

Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock

3/4/2015
SAN DIEGO , March 4, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical device company and manufacturer of the t:slim® and t:flex™ Insulin Pumps, today announced the closing of its previously announced underwritten public offering of 6,037,500 shares of common stock at a price to the public of $11.50 per share, which includes the exercise in ful... [Comments]

GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014

3/4/2015
BEDFORD, Mass., March 4, 2015 GSI Group Inc. (NASDAQ: GSIG ) (the "Company", "we", "our", "GSI"),  a global leader and supplier of precision photonics and motion control components and subsystems to the medical equipment and advanced industrial technology markets, today reported financial results for the fourth quarter and full year 2014. Unless otherwise noted, all financ... [Comments]

Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange

3/4/2015
MENLO PARK, Calif. , March 4, 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger , President and Chief Executive Officer, will ring The Opening Bell ® of the New York Stock Exchange (NYSE) tomorrow, Thursday, March 5, 2015. Asterias began trading as an... [Comments]

Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results

3/4/2015
ATLANTA, March 4, 2015 Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and year ended December 31, 2014. "This past year was a pivotal year for Alimera Sciences, most notably having... [Comments]

Amgen Announces 2015 Second Quarter Dividend

3/4/2015
THOUSAND OAKS, Calif. , March 4, 2015 Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.79 per share dividend for the second quarter of 2015. The dividend will be paid on June 5, 2015, to all stockholders of record as of the close of business on May 14, 2015.  About Amgen Amgen is committed to unlocking the potential of biology for patie... [Comments]

Nevro to Report Operating Results for the Fourth Quarter and Full Year of 2014

3/4/2015
MENLO PARK, Calif. , March 4, 2015  Nevro Corp. (NYSE: NVRO ), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced that it will release financial results for the fourth quarter  and full year of 2014 after market close on Wednesday, March 18, 2015. Co... [Comments]

(Date:3/5/2015)... Ohio (PRWEB) March 05, 2015 ... Gold Development Partner located in Northeast Ohio, today announced ... e2b teknologies to support its upgrade to the latest ... the largest independent group practice of its kind in ... and large volume of transactions, so efficiency and data ...
(Date:3/5/2015)... The next implants made from the PEEK-OPTIMA® ... (European) approval. The CE mark is necessary for distributing ... the European Union. Following the Class IIb approval route, ... supplied by the Turkey-based company Osimplant for the treatment ... Expandable Bladed HA PEEK Cage line of spinal implants, ...
(Date:3/5/2015)... Texas (PRWEB) March 05, 2015 ... of acute and chronic orthopedic conditions such as ... knee, tennis elbow, and joint pain due to ... be administered during orthopedic surgeries to promote better ... scientific advances in nearly pain-free bone marrow harvesting ...
(Date:3/4/2015)... Nev. , March 4, 2015 PDL BioPharma, Inc. ... adjusted conversion rate for the: , 3.75% Convertible ... 174.8506 shares of common stock per $1,000 principal amount or ... The conversion rate for the note is adjusted in connection ... on March 12, 2015, to all stockholders who own shares of ...
Breaking Biology Technology:Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... downward trend three years ago many companies cut their ... as the price of computers dropped, allowing businesses to ... services grew. Many IT staffers are wary of returning ... and looked to begin working as an outside IT ...
... who switch from traditional paper phone bills to SBC ... , ,Through the "Save a StampHelp Save a Life" campaign, ... SBC Services Inc. will contribute $1 dollar for every SBC ... to Nov. 15, 2004. , ,In 2004, an estimated 216,000 ...
... of multimedia resources on children's books including audio of ... launched on a Wisconsin Department of Public Instruction ... TeachingBooks is a new service of BadgerLink , ... and other resources to Wisconsin schools, libraries and homes. , ...
Cached Biology Technology:Expetec expands IT staff services in Wisconsin 2Expetec expands IT staff services in Wisconsin 3TeachingBooks brings free K-12 resources to Wisconsin residents 2
(Date:3/4/2015)... 5. März 2015 Unfors ... im Bereich diagnostische Röntgenstrahlung, stellte heute ... dem European Congress of Radiology (ECR) ... Österreich, einen neuen Strahlungsüberwachungssensor vor. ... Der RaySafe X2-Überwachungssensor ...
(Date:3/4/2015)... Holdings, Inc. (NYSE: HRC ) announced today ... to its Board of Directors.  She most recently served ... as President of Covidien,s Vascular Therapies Division from 2012 to ... 2012. Ms. Enxing Seng joined Covidien in ... she was a founding member and executive officer responsible ...
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
Breaking Medicine Technology:Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor 3Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7